Theriva™ Biologics to Discuss the Trial Design for VIRAGE – a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma – at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed […]